[go: up one dir, main page]

AR045870A1 - Terapia de combinacion para la infeccion de virus de hepatitis c - Google Patents

Terapia de combinacion para la infeccion de virus de hepatitis c

Info

Publication number
AR045870A1
AR045870A1 ARP040103677A ARP040103677A AR045870A1 AR 045870 A1 AR045870 A1 AR 045870A1 AR P040103677 A ARP040103677 A AR P040103677A AR P040103677 A ARP040103677 A AR P040103677A AR 045870 A1 AR045870 A1 AR 045870A1
Authority
AR
Argentina
Prior art keywords
hepatitis
virus infection
combination therapy
combinations
therapeutic combinations
Prior art date
Application number
ARP040103677A
Other languages
English (en)
Inventor
Ene Ette
John J Alam
Robert Stephen Kauffman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR045870A1 publication Critical patent/AR045870A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinaciones terapéuticas que comprenden VX-497, rebavirina, e interferón. Métodos que utilizan estas combinaciones terapéuticas para el tratamiento de la infección de virus hepatitis C o reducción de uno o más síntomas de la misma en un paciente y Kits que comprenden esas combinaciones.
ARP040103677A 2003-10-11 2004-10-08 Terapia de combinacion para la infeccion de virus de hepatitis c AR045870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11

Publications (1)

Publication Number Publication Date
AR045870A1 true AR045870A1 (es) 2005-11-16

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103677A AR045870A1 (es) 2003-10-11 2004-10-08 Terapia de combinacion para la infeccion de virus de hepatitis c

Country Status (17)

Country Link
US (1) US20050112093A1 (es)
EP (1) EP1670462A1 (es)
JP (1) JP2007508326A (es)
KR (1) KR20060120037A (es)
CN (1) CN1882335A (es)
AR (1) AR045870A1 (es)
AU (1) AU2004281747A1 (es)
BR (1) BRPI0415249A (es)
CA (1) CA2541857A1 (es)
IL (1) IL174864A0 (es)
MX (1) MXPA06004077A (es)
NO (1) NO20062104L (es)
PE (1) PE20050477A1 (es)
RU (1) RU2006115916A (es)
TW (1) TW200528104A (es)
WO (1) WO2005037274A1 (es)
ZA (1) ZA200602912B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0932617B1 (en) 1996-10-18 2002-01-16 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
NZ571280A (en) 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
AU2008219704A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
CA2737376A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
WO2011001897A1 (ja) * 2009-06-30 2011-01-06 明治製菓株式会社 難治性のｃ型慢性肝炎の治療のための薬剤及び方法
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SG2014011647A (en) 2011-10-21 2014-08-28 Abbvie Inc Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1515248A (zh) * 1996-04-23 2004-07-28 ��̩��˹ҩ��ɷ����޹�˾ 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
ATE216591T1 (de) * 1998-05-15 2002-05-15 Schering Corp Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
WO2003101199A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors

Also Published As

Publication number Publication date
TW200528104A (en) 2005-09-01
KR20060120037A (ko) 2006-11-24
IL174864A0 (en) 2008-04-13
US20050112093A1 (en) 2005-05-26
AU2004281747A1 (en) 2005-04-28
EP1670462A1 (en) 2006-06-21
MXPA06004077A (es) 2006-06-27
BRPI0415249A (pt) 2006-12-12
JP2007508326A (ja) 2007-04-05
RU2006115916A (ru) 2007-12-10
NO20062104L (no) 2006-05-10
CN1882335A (zh) 2006-12-20
ZA200602912B (en) 2007-06-27
CA2541857A1 (en) 2005-04-28
PE20050477A1 (es) 2005-08-24
WO2005037274A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
CY1116069T1 (el) Θεραπευτικη αγωγη της διαμεσης κυστιτιδας με υψηλη δοση θειικης χονδροϊτινης
BRPI0415935A (pt) combinações para tratamento de hcv
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
EA200401525A1 (ru) Способы лечения гепатита (варианты )
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
WO2004006843A3 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
GB0220257D0 (en) Vaccine
BRPI0406985A (pt) Terapia de combinação de hcv
UA90477C2 (ru) Способ лечения гепатита с (варианты)
UY28555A1 (es) Terapia de combinación para la infección de hcv
ATE383154T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
DK1150981T3 (da) Terapeutisk necleosidforbindelse
ATE447944T1 (de) Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere
UY27766A1 (es) Combinacion de insulina y un derivado de tiazolidindiona y uso de la misma para tratar la diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal